November 30, 2006 -- Cardinal Health will seek to sell its contract manufacturing business, which produced $1.8 billion in revenue and $300 million in EBITDA last year; Durrect out-licensed the European rights for Posidur, a localized post-op pain relief depot, to Nycomed; Ligand will begin a Phase I trial of an oral drug that promotes the growth and production of blood platelets; Hollis-Eden reported that its oral synthetic steroid hormone was very effective in a rodent model of rheumatoid arthritis; and Amgen fell 2% on more concern about over-prescription of anti-anemia drugs. The Centient Biotech 200™ was off by 26 points at 3957, a loss of .64%. More details...
